# A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Source: https://onco.cc/trials/nct06008288/  
OnCo record `nct06008288` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Glecirasib in pancreatic ductal adenocarcinoma, run by Allist Pharmaceuticals, Inc., now recruiting.

## Summary

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. is a phase 2 interventional study registered as NCT06008288 by Allist Pharmaceuticals, Inc., with 88 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: JAB-21822.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06008288
- Phase: 2
- Setting: A Single-arm, Multicenter, Open-label Phase II Clinical Study Evaluating the Efficacy and Safety of JAB-21822 Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT06008288: https://clinicaltrials.gov/study/NCT06008288

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Glecirasib](https://onco.cc/drugs/glecirasib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct06008288.json